| URL | https://www.novartis.com/news/media-releases/novar |
| Source | https://www.novartis.com |
| Date Published | 04/05/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Novartis |
| Parent company | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapies, Zolgensma® |